Document:

Exhibit 10.1

AMENDMENT TO

TECHNOLOGY DEVELOPMENT AND OPTION AGREEMENT

     This AMENDMENT TO TECHNOLOGY DEVELOPMENT AND OPTION AGREEMENT (this "Amendment") is entered into as of August 18, 2008, between SGPF, LLC, a Kentucky limited liability company (“SGPF”) and MEDPRO SAFETY
PRODUCTS, INC, a Kentucky limited liability company (“MedPro”).

RECITALS:

     A. MedPro and SGPF are parties to that certain TECHNOLOGY DEVELOPMENT AND OPTION AGREEMENT dated effective August 24, 2007 (the "Agreement"). Capitalized terms not otherwise defined herein shall have the meanings
assigned them in the Agreement.

     B. Vision Opportunity Master Fund, Ltd. (“Vision”) has agreed to exercise its J Warrants in MedPro, provided that the parties agree to amend certain provisions of the Agreement.

     C. SGPF is agreeable to amending the Agreement provided that Vision exercises the J Warrants in full and MedPro exercises its right to purchase the Blunt Technology under the terms of the Agreement.

     NOW, THEREFORE, in consideration of the mutual promises hereby made, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

     1. Amendments. Subject to Paragraph 2 below, the Agreement is hereby amended as follows:

	
(a)              	
Section 3.2(i)(a) is hereby replaced and amended in its entirety as follows:    

  
“the sum of Three Million Three Hundred and Forty Five Thousand Dollars ($3,345,000.00);”

	
(b)              	
Section 3.2(i)(b) is hereby deleted;    
	 	 
	
(c)              	
Section 3.2(i)(c) is hereby replaced and amended in its entirety as follows:    

  
“the sum of One Million Two Hundred and Fifty Thousand Dollars ($1,250,000.00) in common stock of MedPro (or any other shares into which MedPro common stock may be converted) based on a value of $1.81 per share of the MedPro common
stock.”

     2. Visual Connections. MedPro shall pay the outstanding balance of the amount payable to Visual Connections under Section 2(a) of the TAG.

     3. Condition Precedent to Amendment. This Amendment shall not take effect unless on or before September 30, 2008 Vision exercises its J Warrants to purchase shares of MedPro’s Series B Convertible Preferred
Stock for at least $6.5 million in cash, and MedPro exercises it right to purchase the Blunt Technology under the Agreement, time being of the essence.

     4. Conflicting Language. To the extent that any language contained in the Agreement conflicts with any language contained in this Amendment, the language contained in this Amendment shall control.

     5. Full Force and Effect. Except as expressly amended by this Amendment, the Agreement remains unchanged and in full force and effect.

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

2

     IN WITNESS WHEREOF, the parties

hereto

have

executed

and

delivered

this

Amendment as of the date first set forth above.
 

	
SGPF:
        	
SGPF, LLC
        
	 	 	 
	 

        	
By:
        	
/s/ W. Craig Turner
      

        
	 

        	
Title:
        	
Managing Partner
        
	 

        	
Date:
        	
September 8, 2008
        
	 

        
	
MEDPRO:
        	
MEDPRO SAFETY PRODUCTS, INC
        
	 	 	 
	 

        	
By:
        	
/s/ Walter W. Weller
      

        
	 

        	
Title:
        	
President and C.O.O.
        
	 

        	
Date:
        	
September 8, 2008
        

S-1exv10w1

Exhibit 10.1

[Endocare, Inc. Letterhead]

October 2, 2008

Dear Terry:

It is a pleasure to extend you an offer of employment to join Endocare, Inc. (the “Company”) as
Interim Chief Executive Officer and Interim President, reporting to the Company’s Board of
Directors. This position qualifies as a Section 16 Officer. Your employment with Endocare
commences on October 2, 2008. In addition, you will continue as a member of the Company’s Board of
Directors. The following information outlines the details of this offer:

	 	 	 
	Employment Status:
	 	Regular, full time, exempt status.
	 	 	 
	Compensation:
	 	Your salaried rate will be $12,500 per pay period
(annualized at $300,000 per year), with pay periods on
the 5th and the 20th of each
month.
	 	 	 
	Benefits:
	 	You will be eligible for Endocare’s employee Benefits
Program in accordance with Endocare’s current
policies. Additional details regarding these plans
and the effective date of your eligibility under each
will be forthcoming.
	 	 	 
	Stock Options:
	 	On October 2, 2008, the Compensation Committee will
grant to you 50,000 incentive stock options under the
Company’s 2004 Stock Incentive Plan. The exercise
price of these stock options will be the closing price
of the Company’s Common Stock on The NASDAQ Capital
Market on October 2, 2008. The stock options will
vest in five equal monthly installments on November 2,
2008, December 2, 2008, January 2, 2009, February 2,
2009 and March 2, 2009, with vesting accelerated if
the Company appoints a new Chief Executive Officer
before March 2, 2009 and you remain employed by the
Company until such appointment. Additional terms
applicable to the grant will be outlined in a stock
option agreement, which will be based on the standard
form stock option agreement under the Company’s 2004
Stock Incentive Plan.
	 	 	 
	Term of Employment:
	 	While we hope your employment relationship with
Endocare will be mutually beneficial, it should be
recognized that neither you, nor we, have entered into
any contract of employment, express or implied. Your
employment relationship with Endocare is “at will.”
This means that your employment may be terminated at
any time, with or without cause, and with or without
notice by you or by the Company. Any contrary

 

 

Terrence A. Noonan

Offer Letter

October 2, 2008

Page 2 of 2

	 	 	 
	 

	 	representations or agreements which may have been made
to you are superseded by this offer. The at-will
nature of your employment described in this offer
letter shall constitute the entire agreement between
you and the Company concerning the duration of your
employment and the circumstances under which either
you or the Company may terminate the employment
relationship. No person affiliated with the Company
has the authority to enter into any oral agreement
that changes your at-will status of employment with
the Company. This “at will” relationship can only be
changed by action of the Compensation Committee of our
Board of Directors. By signing below and accepting
this offer, you acknowledge and agree that length of
employment, promotions, positive performance reviews,
pay increases, bonuses, increases in job duties or
responsibilities, and other changes during employment
will not change the at will term of your employment
with the Company and will not create any implied
contract requiring cause for termination of
employment.
	 
	 	 
	Conditional Offer:

	 	This offer is contingent upon your producing documents
required under the Immigration Reform and Control Act
establishing your legal right to work in the United
States; favorable reference checks, criminal
background, and education verification results; and
your signing the Company’s agreements regarding
confidentiality, proprietary information, and
arbitration, as well as other necessary employment
documents that will be provided to you.

On behalf of Endocare, I’d like to thank you for your willingness to serve as our Interim Chief
Executive Officer and Interim President. To indicate your acceptance, please sign below and return
to Human Resources. Should you have any questions or concerns regarding the offer, please feel
free to contact me at (949) 450-5404.

Sincerely,

/s/ Suzanne Douglass

Suzanne Douglass

Vice President, Human Resources

					
	 	 	 	 	 
	Agreed and Accepted by:
	 	/s/ Terrence A. Noonan
	 	  10/2/08
	 
	 	 
	 	 
	 
	 	Terrence A. Noonan
	 	Dateexv4w1

EXHIBIT 4.1

THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION, AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933 AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

ECHO THERAPEUTICS, INC.

WARRANT TO PURCHASE COMMON STOCK

			
	Warrant No.                     
	 	Original Issue Date: September 30, 2008

Expiration Date: October 1, 2013

Echo Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for value
received, [                    ] (the “Holder”) is entitled to purchase from the Company up to a total
of [                     (                )] shares of common stock, $0.01 par value per share (the “Common
Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant
Shares”) at an exercise price per Warrant Share equal to $1.00 (as adjusted from time to time as
provided in Section 9 herein, the “Exercise Price”), at any time until, and from time to time after
the date hereof (the “Trigger Date”) to and including, 5:30 P.M., New York City time, on October 1,
2013 (the “Expiration Date”), and subject to the following terms and conditions:

1. Recital. This Warrant (this “Warrant”) is one of a series of similar warrants issued
pursuant to that certain Exchange Agreement, dated September 30, 2008, by and among the Company and
the Investors identified therein (the “Agreement”). All such warrants are referred to herein,
collectively, as the “Warrants.”

2. Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized
terms that are not otherwise defined herein shall have the meanings given to such terms in the
Agreement.

3. Registration of Warrants. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the “Warrant Register”), in the name of the record
Holder from time to time. The Company may deem and treat the registered Holder of this Warrant as
the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

4. Exercise and Duration of Warrant.

     (a) All or any part of this Warrant shall be exercisable by the registered Holder in any
manner permitted by Section 10 of this Warrant at any time until, and from time to time on or after
the Trigger Date to and including, 5:30 P.M. New York City time, on the Expiration Date. At 5:30
P.M., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior
thereto shall be and become void and of no value and this Warrant shall be terminated and no longer
outstanding.

 

 

     (b) The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice,
in the form attached as Schedule 1 hereto (the “Exercise Notice”), completed and duly
signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this
Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated in the
Exercise Notice and if a “cashless exercise” may occur at such time pursuant to Section 10 below).
The date such items are delivered to the Company (as determined in accordance with the notice
provisions hereof) is an “Exercise Date.” The delivery by (or on behalf of) the Holder of the
Exercise Notice and the applicable Exercise Price as provided above shall constitute the Holder’s
certification to the Company that its representations contained in Section 2.1(c), (d) and (e) of
the Agreement are true and correct as of the Exercise Date as if remade in their entirety. The
Holder shall not be required to deliver the original Warrant in order to effect an exercise
hereunder, but if it is not so delivered then such exercise shall constitute an agreement by the
Holder to deliver the original Warrant to the Company as soon as practicable thereafter. Execution
and delivery of the Exercise Notice shall have the same effect as cancellation of the original
Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of
Warrant Shares.

5. Delivery of Warrant Shares.

     (a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than five
(5) Trading Days after the Exercise Date) issue or cause to be issued and cause to be delivered to
or upon the written order of the Holder and in such name or names as the Holder may designate (i) a
certificate for the Warrant Shares issuable upon such exercise, free of restrictive legends, or
(ii) an electronic delivery of the Warrant Shares to the Holder’s account at the Depository Trust
Company or a similar organization, unless in the case of clause (i) and (ii) a registration
statement covering the resale of the Warrant Shares and naming the Holder as a selling stockholder
thereunder is not then effective or the Warrant Shares are not freely transferable without
restriction (including requirement for current public information pursuant to Rule 144(c)) under
Rule 144 by Holders who are not affiliates of the Company, in which case such Holder shall receive
a certificate for the Warrant Shares issuable upon such exercise with appropriate restrictive
legends. The Holder, or any Person permissibly so designated by the Holder to receive Warrant
Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the
Exercise Date. If the Warrant Shares are to be issued free of all restrictive legends, the Company
shall, upon the written request of the Holder, use its reasonable best efforts to deliver, or cause
to be delivered, Warrant Shares hereunder electronically through the Depository Trust Company or
another established clearing corporation performing similar functions, if available; provided,
that, the Company may, but will not be required to, change its transfer agent if its current
transfer agent cannot deliver Warrant Shares electronically through such a clearing corporation.

     (b) If by the close of the fifth Trading Day after delivery of an Exercise Notice and the
payment of the aggregate exercise price in any manner permitted by Section 10 of this Warrant, the
Company fails to deliver to the Holder a certificate representing the required number of Warrant
Shares in the manner required pursuant to Section 5(a), and if after such fifth Trading Day and
prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or
otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant
Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company
shall, within five (5) Trading Days after the Holder’s request and in the Holder’s sole discretion,
either (1) pay in cash to the Holder an amount equal to the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so

2

 

purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such
certificate (and to issue such Warrant Shares) shall terminate or (2) promptly honor its obligation
to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay
cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product
of (A) such number of Warrant Shares, times (B) the closing bid price of a share of Common Stock on
the Exercise Date.

     (c) To the extent permitted by law, the Company’s obligations to issue and deliver Warrant
Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any
action or inaction by the Holder to enforce the same, any waiver or consent with respect to any
provision hereof, the recovery of any judgment against any Person or any action to enforce the
same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged
breach by the Holder or any other Person of any obligation to the Company or any violation or
alleged violation of law by the Holder or any other Person, and irrespective of any other
circumstance that might otherwise limit such obligation of the Company to the Holder in connection
with the issuance of Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any
other remedies available to it hereunder, at law or in equity including, without limitation, a
decree of specific performance and/or injunctive relief with respect to the Company’s failure to
timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as
required pursuant to the terms hereof.

6. Charges, Taxes and Expenses. Issuance and delivery of certificates for Warrant Shares
upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer
tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such
certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that
the Company shall not be required to pay any tax that may be payable in respect of any transfer
involved in the registration of any certificates for Warrant Shares or the Warrants in a name other
than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax
liability that may arise as a result of holding or transferring this Warrant or receiving Warrant
Shares upon exercise hereof.

7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the
Company shall issue or cause to be issued in exchange and substitution for and upon cancellation
hereof, or in lieu of and substitution for this Warrant, a new Warrant, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case)
and, in each case, a customary and reasonable indemnity and surety bond, if requested by the
Company. Applicants for a new Warrant under such circumstances shall also comply with such other
reasonable regulations and procedures and pay such other reasonable third-party costs as the
Company may prescribe. If a new Warrant is requested as a result of a mutilation of this Warrant,
then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the
Company’s obligation to issue the new Warrant.

8. Reservation of Warrant Shares. The Company covenants that it will at all times reserve
and keep available out of the aggregate of its authorized but unissued and otherwise unreserved
Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this
Warrant as herein provided, 110% of the number of Warrant Shares that are then issuable and
deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other
contingent purchase rights of persons other than the Holder (taking into account the adjustments
and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and
deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance
with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable.

3

 

The Company will take all such action as may be reasonably necessary to assure that such shares of
Common Stock may be issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any securities exchange or automated quotation service upon
which the Common Stock may be listed or quoted from time to time.

9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon
exercise of this Warrant are subject to adjustment from time to time as set forth in this Section
9.

     (a) Stock Dividends and Splits. If the Company, at any time while this Warrant is
outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any
class of capital stock that is payable in shares of Common Stock, (ii) subdivides its outstanding
shares of Common Stock into a larger number of shares, or (iii) combines its outstanding shares of
Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be
multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock
outstanding immediately before such event and the denominator of which shall be the number of
shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to
clause (i) of this paragraph shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution, and any adjustment
pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the
effective date of such subdivision or combination.

     (b) Pro Rata Distributions. If the Company, at any time while this Warrant is
outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its
indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding
paragraph) or (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other
asset (in each case, “Distributed Property”), then, upon any exercise of this Warrant that occurs
after the record date fixed for determination of stockholders entitled to receive such
distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise
issuable upon such exercise (if applicable), the Distributed Property that such Holder would have
been entitled to receive in respect of such number of Warrant Shares had the Holder been the record
holder of such Warrant Shares immediately prior to such record date without regard to any
limitation on exercise contained therein.

     (c) Fundamental Transactions. If, at any time while this Warrant is outstanding (i)
the Company effects (A) any merger of the Company with (but not into) another Person, in which
stockholders of the Company immediately prior to such transaction own less than a majority of the
outstanding stock of the surviving entity, or (B) any merger or consolidation of the Company into
another Person, (ii) the Company effects any sale of all or substantially all of its assets in one
or a series of related transactions, (iii) any tender offer or exchange offer approved or
authorized by the Company’s Board of Directors is completed pursuant to which holders of at least a
majority of the outstanding Common Stock tender or exchange their shares for other securities, cash
or property, or (iv) the Company effects any reclassification of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property (other than as a result of a subdivision or combination of
shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental
Transaction”), then the Holder shall have the right thereafter to receive, upon exercise of this
Warrant, the same amount and kind of securities, cash or property as it would have been entitled to
receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to
such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon
exercise in full of this Warrant without regard to any limitations on exercise contained herein
(the “Alternate Consideration”), and the Holder shall

4

 

no longer have the right to receive Warrant Shares upon exercise of this Warrant. The Company shall not effect any such
Fundamental Transaction unless prior to or simultaneously with the consummation thereof, any
successor to the Company, surviving entity or the corporation purchasing or otherwise acquiring
such assets or other appropriate corporation or Person shall assume the obligation to deliver to
the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the
Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of
this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental
Transaction type.

     (d) First Qualified Offering. If the Company, at any time while this Warrant is
outstanding, completes an equity or equity-linked offering to occur after the Original Issue Date
that yields gross proceeds to the Company of at least $2 million (the “Qualified Offering”), the
Exercise Price shall be reduced to the lesser of (i) the then current Exercise Price in effect, or
(ii) the price per share of the common stock issued in the Qualified Offering or in the case of
convertible securities, the conversion price of such convertible securities. This right shall
expire after the completion of the first Qualified Offering completed by the Company.

     (e) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price
pursuant to paragraph (a) of this Section 9, the number of Warrant Shares that may be purchased
upon exercise of this Warrant shall be increased or decreased proportionately, so that after such
adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of
Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to
such adjustment.

     (f) Calculations. All calculations under this Section 9 shall be made to the nearest
cent or the nearest 1/100th of a share, as applicable. The number of shares of Common Stock
outstanding at any given time shall not include shares owned or held by or for the account of the
Company, and the disposition of any such shares shall be considered an issue or sale of Common
Stock.

     (g) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this
Section 9, the Company at its expense will, at the written request of the Holder, promptly compute
such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a
certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and
adjusted number or type of Warrant Shares or other securities issuable upon exercise of this
Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in
reasonable detail the facts upon which such adjustment is based. Upon written request, the Company
will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer
agent.

     (h) Notice of Corporate Events. If, while this Warrant is outstanding, the Company (i)
declares a dividend or any other distribution of cash, securities or other property in respect of
its Common Stock, including, without limitation, any granting of rights or warrants to subscribe
for or purchase any capital stock of the Company or any Subsidiary, (ii) authorizes or approves,
enters into any agreement contemplating or solicits stockholder approval for any Fundamental
Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs
of the Company, then, except if such notice and the contents thereof shall be deemed to constitute
material non-public information, the Company shall deliver to the Holder a notice describing the
material terms and conditions of such transaction at least ten (10) business days prior to the
applicable record or effective date on which a Person would need to hold Common Stock in order to
participate in or vote with respect to such transaction; provided, however, that the failure to

5

 

deliver such notice or any defect therein shall not affect the validity of the corporate
action required to be described in such notice.

10. Payment of Exercise Price. The Holder shall pay the Exercise Price in immediately
available funds; provided, however, that if, on any Exercise Date that is more than 12 months after
the Trigger Date there is not an effective registration statement registering, or no current
prospectus available for, the resale of the Warrant Shares by the Holder pursuant to the Securities
Act of 1933, as amended (the “Securities Act”), then the Holder may, in its sole discretion,
satisfy its obligation to pay the Exercise Price through a “cashless exercise”, in which event the
Company shall issue to the Holder the number of Warrant Shares determined as follows:

X = Y [(A-B)/A]

  where:

X = the number of Warrant Shares to be issued to the Holder.

Y = the total number of Warrant Shares with respect to which this Warrant is
being exercised.

A = the average of the Closing Sale Prices of a share of Common Stock (as
reported by Bloomberg Financial Markets) for the five (5) Trading Days ending on
the date immediately preceding the Exercise Date.

B = the Exercise Price then in effect for the applicable Warrant Shares at the
time of such exercise.

For purposes of this Warrant, “Closing Sale Price” means, for any security as of any date, the last
trade price for such security on the principal securities exchange or trading market for such
security, as reported by Bloomberg Financial Markets, or, if such exchange or trading market begins
to operate on an extended hours basis and does not designate the last trade price, then the last
trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg
Financial Markets, or if the foregoing do not apply, the last trade price of such security in the
over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg
Financial Markets, or, if no last trade price is reported for such security by Bloomberg Financial
Markets, the average of the bid prices, or the ask prices, respectively, of any market makers for
such security as reported in the “pink sheets” by Pink Sheets LLC. If the Closing Sale Price
cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing
Sale Price of such security on such date shall be the fair market value as mutually determined by
the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market
value of such security, then the Board of Directors of the Company shall use its good faith
judgment to determine the fair market value. The Board of Directors’ determination shall be
binding upon all parties absent demonstrable error. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination or other similar transaction during
the applicable calculation period.

For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and
acknowledged that the Warrant Shares issued in a cashless exercise transaction shall be deemed to
have been acquired by the original Holder, and the holding period for the Warrant Shares shall be
deemed to have commenced as to such original Holder, on the date this Warrant was originally

6

 

issued pursuant to the Agreement (provided that the Commission continues to take the position that
such treatment is proper at the time of such exercise).

11. Limitations on Exercise.

     (a) Notwithstanding anything to the contrary set forth in this Warrant, at no time may a
Holder of this Warrant exercise this Warrant if the number of Warrant Shares to be issued pursuant
to such exercise would exceed, when aggregated with all other shares of Common Stock owned by such
Holder at such time, the number of shares of Common Stock which would result in such Holder
beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), and the rules thereunder) in excess of 4.99% of all of
the Common Stock outstanding at such time; provided, however, that upon a Holder of
this Warrant providing the Company with sixty-one (61) days notice (the “Waiver Notice”)
that such Holder would like to waive this Section 11(a) with regard to any or all Warrant Shares
issuable upon exercise of this Warrant, this Section 11(a) will be of no force or effect with
regard to all or a portion of the Warrant Shares referenced in the Waiver Notice; provided,
further, that this Section 11(a) shall be of no further force or effect during the sixty-one (61)
days immediately preceding the expiration of the term of this Warrant.

     (b) Notwithstanding anything to the contrary set forth in this Warrant, at no time may a
Holder of this Warrant exercise this Warrant if the number of Warrant Shares to be issued pursuant
to such exercise would exceed, when aggregated with all other shares of Common Stock owned by such
Holder at such time, the number of shares of Common Stock which would result in such Holder
beneficially owning (as determined in accordance with Section 13(d) of the Exchange Act and the
rules thereunder) in excess of 9.99% of all of the Common Stock outstanding at such time; provided,
however, that upon a Holder of this Warrant providing the Company with a Waiver Notice with regard
to this Section 11(b), this Section 11(b) will be of no force or effect with regard to all or a
portion of the Warrant Shares referenced in such Waiver Notice; provided, further, that this
Section 11(b) shall be of no further force or effect during the sixty-one (61) days immediately
preceding the expiration of the term of this Warrant.

12. No Fractional Warrant Shares. No fractional Warrant Shares will be issued in connection
with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be
issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number
and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale
Price) for any such fractional Warrant Shares.

13. Notices. Any and all notices or other communications or deliveries hereunder
(including, without limitation, any Exercise Notice or Waiver Notice) shall be in writing and shall
be deemed given and effective on the earliest of (i) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number specified in the Agreement prior
to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile at the facsimile number
specified in the Agreement on a day that is not a Trading Day or later than 5:30 P.M., New York
City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by
nationally recognized overnight courier service specifying next business day delivery, or (iv) upon
actual receipt by the party to whom such notice is required to be given, if by hand delivery. The
address and facsimile number of a party for such notices or communications shall be as set forth in
the Agreement unless changed by such party by two (2) Trading Days’ prior notice to the other party
in accordance with this Section 13.

7

 

14. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty
(30) days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into
which the Company or any new warrant agent may be merged or any corporation resulting from any
consolidation to which the Company or any new warrant agent shall be a party or any corporation to
which the Company or any new warrant agent transfers substantially all of its corporate trust or
shareholders services business shall be a successor warrant agent under this Warrant without any
further act. Any such successor warrant agent shall promptly cause notice of its succession as
warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s
last address as shown on the Warrant Register.

15. Miscellaneous.

     (a) No Rights as a Stockholder. The Holder, solely in such Person’s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder
of share capital of the Company for any purpose, nor shall anything contained in this Warrant be
construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this
Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold
consent to any corporate action (whether any reorganization, issue of stock, reclassification of
stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings,
receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the
Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant.
In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on
the Holder to purchase any securities, whether such liabilities are asserted by the Company or by
creditors of the Company.

     (b) Successors and Assigns. This Warrant may not be assigned by the Company or the
Holder without the written consent of the other party, except to a successor in the event of a
Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the parties
hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in
this Warrant shall be construed to give to any Person other than the Company and the Holder any
legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended
only in writing signed by the Company and the Holder, or their successors and assigns.

     (c) Amendment and Waiver. Except as otherwise provided herein, the provisions of the
Warrant may be amended and the Company may take any action herein prohibited, or omit to perform
any act herein required to be performed by it, only if the Company has obtained the written consent
of the Holders of Warrants representing a majority of the Warrant Shares obtainable upon exercise
of the Warrants then outstanding.

     (d) Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to all of the terms and conditions contained herein.

     (e) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY,
ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF
LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND
FEDERAL COURTS SITTING IN THE STATE OF NEW YORK, FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY

8

 

TRANSACTION CONTEMPLATED HEREBY
OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION
DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR
PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH
PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN
ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR
OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES
TO IT UNDER THE AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE
OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY
RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH PARTY HEREBY WAIVES ALL RIGHTS TO A
TRIAL BY JURY.

     (f) Headings. The headings herein are for convenience only, do not constitute a part
of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

     (g) Severability. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and
provisions of this Warrant shall not in any way be affected or impaired thereby, and the parties
will attempt in good faith to agree upon a valid and enforceable provision which shall be a
commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Warrant.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,

SIGNATURE PAGE FOLLOWS]

9

 

     IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized
officer as of the date first indicated above.

	 	 	 	 	 
	 	ECHO THERAPEUTICS, INC.

 	 
	 	By:  	 	 
	 	Name:  	 	 	 
	 	Title:  	 	 	 
	 

 

 

SCHEDULE 1

ECHO THERAPEUTICS, INC.

FORM OF EXERCISE NOTICE

(To be executed by the Holder to purchase shares of Common Stock under the foregoing Warrant)

Ladies and Gentlemen:

(1) The undersigned is the Holder of Warrant No.                      (the “Warrant”) issued by Echo
Therapeutics, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and not
otherwise defined herein have the respective meanings set forth in the Warrant.

(2) The undersigned hereby exercises its right to purchase                      Warrant Shares pursuant to
the Warrant.

(3) The Holder intends that payment of the Exercise Price shall be made as (check one):

	 	o	 	Cash Exercise
	 
	 	o	 	“Cashless Exercise” under Section 10

(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $                     in
immediately available funds to the Company in accordance with the terms of the Warrant.

(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares
determined in accordance with the terms of the Warrant.

(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company
that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in
excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of
the Securities Exchange Act of 1934) permitted to be owned under Section 11 of the Warrant to which
this notice relates.

Dated:                                        ,           

	 	 	 	 	 
	Name of Holder:

	 	 
 

	 	 

	 	 	 	 	 
	By: 

Name:

	 	 
 
 
	 	 
	Title:

	 	 

 
 

	 	  

(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]